Aboalmagd Hamdallah

Aboalmagd Hamdallah

Auto-generated profile, based on publicly available information

Aboalmagd Hamdallah

Faculty of Medicine, Al-Azhar University, Damietta, Egypt

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem
AHAboalmagd Hamdallah
Aboalmagd Hamdallah
MRMarwa Abdelazim Rizk
Marwa Abdelazim Rizk
KAKirellos Said Abbas
Kirellos Said Abbas
NENahla Ahmed El-Shahat
Nahla Ahmed El-Shahat
MEMostafa Eltobgy
Mostafa Eltobgy
Background: Surveys are an effective method for collecting a large quantity of data. However, incomplete responses to these surveys can affect the validity of the studies and introduce bias. Recent studies have suggested that monetary incentives may increase survey response rates. We intended to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the effect of monetary incentives on survey participation.Methods: A systematic search of electronic databases was conducted to collect studies assessing the impact of monetary incentives on survey participation. The primary outcome of interest was the response rates to incentives: money, lottery, and voucher. We used the Cochrane Collaboration tool to assess the risk of bias in randomized trials. We calculated the rate ratio (RR) with its 95% confidence interval (95% CI) using Review Manager Software (version 5.3). We used random-effects analysis and considered the data statistically significant with a P-value <0.05.Results: Forty-six RCTs were included. A total of 109,648 participants from 14 countries were involved. The mean age of participants ranged from 15 to more than 60 years, with 27.5% being males, 16.7% being females, and the other 55.8% not reported. Our analysis showed a significant increase in response rate in the incentive group compared to the control group, irrespective of the incentive methods. Money was the most efficient way to increase the response rate (RR: 1.25; 95% CI: 1.16,1.35; P = < 0.00001) compared to voucher (RR: 1.19; 95% CI: 1.08,1.31; P = < 0.0005) and lottery (RR: 1.12; 95% CI: 1.03,1.22; P = < 0.009).Conclusion: Monetary incentives encourage the response rate in surveys. Money was more effective than vouchers or lotteries. Therefore, researchers may include money as an incentive to improve the response rate while conducting surveys.

21 July 2020 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
PDF file
YAYossef Hassan AbdelQadir
Yossef Hassan AbdelQadir
AHAboalmagd Hamdallah
Aboalmagd Hamdallah
ESEsraa Alsayed Sibaey
Esraa Alsayed Sibaey
AHAlyaa Sayed Hussein
Alyaa Sayed Hussein
MAMuhammad Abdelaziz
Muhammad Abdelaziz
ANAnas Nourelden
Anas Nourelden

20 May 2022 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
MZMohamed Sayed Zaazouee
Mohamed Sayed Zaazouee
AHAboalmagd Hamdallah
Aboalmagd Hamdallah
SHSara Kamel Helmy
Sara Kamel Helmy
EHElfatih A. Hasabo
Elfatih A. Hasabo
ASAhmed Kamal Sayed
Ahmed Kamal Sayed
ANAnas Nourelden
Anas Nourelden

23 November 2022 in The Journal of the American Dental Association
Verified
Journal Article
Closed access
HMHossam Waleed Madhoon
Hossam Waleed Madhoon
AHAboalmagd Hamdallah
Aboalmagd Hamdallah
MEMohammed Abu Eida
Mohammed Abu Eida
MAMohammed Al-Kafarna
Mohammed Al-Kafarna
DADuha Ahmad Atallah
Duha Ahmad Atallah
NANabeel Almotairy
Nabeel Almotairy

1 May 2021 in Current Rheumatology Reviews
Verified
Journal Article
Closed access
PDF file
LSLaila Salah Shamseldin
Laila Salah Shamseldin
MSMohamed Mohamed Shawqi
Mohamed Mohamed Shawqi
NHNoor Adel Al Hashem
Noor Adel Al Hashem
MAMajd Aleslam Hussein Alhyari
Majd Aleslam Hussein Alhyari
HEHossam Aldein Samir Abd Elazeem
Hossam Aldein Samir Abd Elazeem
ANAnas Zakarya Nourelden
Anas Zakarya Nourelden
Background: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by progressive swelling and stiffness in the joints. Mavrilimumab is a human monoclonal antibody that may block the autoimmune mechanism of the antibodies causing RA. Objective: We aim to assess the safety and efficacy of Mavrilimumab in treating rheumatoid arthritis. Methods: We conducted an online search using PubMed, Scopus, Web of Science, and Cochrane CENTRAL till June 2019, and updated the search in May 2020, using relevant keywords. We screened studies for eligibility. Data were extracted from eligible studies and pooled as Risk ratio (RR) with a 95% confidence interval (CI), using Review Manager software (ver.3.5). Results: Five studies (with 1145 patients) were eligible to our criteria. Pooled result from three trials showed a significant reduction in Disease Activity Score 28 based on C-reactive protein (DAS28-CRP) remission < 2.6 after 12 weeks (RR = 3.31, 95% CI [1.53, 7.18], P = 0.002), American College of Rheumatology (ACR) 20, after 12 weeks (RR = 2.38, 95% CI [1.80, 3.16], P < 0.00001), ACR 50, after 12 weeks (RR = 2.93, 95% CI [1.67, 5.15], P = 0.0002), ACR 70, after 12 weeks (RR = 4.90, 95% CI [1.60, 15.00], P = 0.005). Mavrilimumab not associated with a significant adverse event (RR = 1.22, 95% CI [0.89, 1.68], P = 0.22). Conclusion: We found that subcutaneous Mavrilimumab was effective and well-tolerating in treating RA patients, with no significant adverse events.